Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Commissioner Controversy Delays “Behind-The-Counter” Rx Precedent

Executive Summary

FDA appears to be ready to create a new class of "behind the counter" OTC drugs

You may also be interested in...

FDA Confirmation Process Hits A Roadblock: Time For Plan B?

Acting FDA Commissioner Lester Crawford's prospects for Senate confirmation appear to be in jeopardy after the Health Committee disclosed concerns about a conduct allegation lodged against the nominee

FDA Commissioner Nomination On Hold Pending Plan B Decision

Senate Health Committee Democrats are threatening to delay the confirmation of Lester Crawford as commissioner until the agency makes a decision about Barr's application to switch the emergency contraceptive Plan B to OTC status

Senate Health Democrats Press Crawford For Plan B Decision Timeline

Senate Health Committee Democrats are asking to meet with FDA Commissioner nominee Lester Crawford to discuss the Rx-to-OTC switch of emergency contraceptive Plan B prior to voting on his confirmation





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts